Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Establishing post mortem criteria for the metabolic syndrome: an autopsy based cross-sectional study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative review

    Research output: Contribution to journalReviewResearchpeer-review

  1. Potassium Disturbances and Risk of Ventricular Fibrillation Among Patients With ST-Segment-Elevation Myocardial Infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessment of Islet Alpha- and Beta-Cell Function

    Research output: Chapter in Book/Report/Conference proceedingBook chapterCommunication

  4. Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Hyperinsulinemia aggravates insulin resistance and cardio-vascular disease. How the insulinotropic glucagon-like peptide-1 receptor agonist liraglutide in a physiologic post-prandial setting may act on pancreatic alpha and beta-cell function in patients with coronary artery disease (CAD) and type 2 diabetes (T2DM) is less clear. Methods: Insulin resistant patients with established CAD and newly diagnosed well-controlled T2DM were recruited to a placebo-controlled, cross-over trial with two treatment periods of 12 weeks and a 2 weeks wash-out period before and in-between. Treatment was liraglutide or placebo titrated from 0.6 mg q.d. to 1.8 mg q.d. within 4 weeks and metformin titrated from 500 mg b.i.d to 1000 mg b.i.d. within 4 weeks. Before and after intervention in both 12 weeks periods insulin, C-peptide, glucose, and glucagon were measured during a meal test. Beta-cell function derived from the oral glucose tolerance setting was calculated as changes in insulin secretion per unit changes in glucose concentration (B total) and whole-body insulin resistance using ISI composite. Results: Liraglutide increased the disposition index [B total × ISI composite, by 40% (n = 24, p < 0.001)] compared to placebo. Post-prandial insulin and glucose was reduced by metformin in combination with liraglutide and differed, but not significantly different from placebo, moreover, glucagon concentration was unaffected. Additionally, insulin clearance tended to increase during liraglutide therapy (n = 26, p = 0.06). Conclusions: The insulinotropic drug liraglutide may without increasing the insulin concentration reduce postprandial glucose but not glucagon excursions and improve beta-cell function in newly diagnosed and well-controlled T2DM. Trial registration Clinicaltrials.gov ID: NCT01595789

Original languageEnglish
Article number42
JournalDiabetology & Metabolic Syndrome
Volume11
Issue number1
Pages (from-to)42
ISSN1758-5996
DOIs
Publication statusPublished - 31 May 2019

    Research areas

  • Beta-cell function, Diabetes mellitus type 2, GLP1-receptor agonist, Glucagon, Insulin clearance, Insulin sensitivity, Meal test

ID: 57306426